Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System decreased its holdings in shares of Alliant Energy Corporation (NASDAQ:LNT – Free Report) by 32.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 436,395 shares of the company’s stock after selling 207,817 shares during the quarter. California Public Employees Retirement System owned about 0.17% of Alliant Energy worth $31,316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Glenmede Investment Management LP lifted its stake in shares of Alliant Energy by 0.7% during the third quarter. Glenmede Investment Management LP now owns 22,793 shares of the company’s stock worth $1,536,000 after purchasing an additional 153 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of Alliant Energy by 1.8% in the third quarter. Quadrant Capital Group LLC now owns 9,117 shares of the company’s stock valued at $615,000 after buying an additional 158 shares in the last quarter. Apollon Wealth Management LLC grew its stake in shares of Alliant Energy by 4.8% in the fourth quarter. Apollon Wealth Management LLC now owns 3,517 shares of the company’s stock valued at $229,000 after buying an additional 161 shares in the last quarter. Simplicity Wealth LLC raised its holdings in shares of Alliant Energy by 5.5% during the 4th quarter. Simplicity Wealth LLC now owns 3,216 shares of the company’s stock valued at $209,000 after buying an additional 167 shares during the period. Finally, Resonant Capital Advisors LLC lifted its position in Alliant Energy by 4.6% during the 1st quarter. Resonant Capital Advisors LLC now owns 4,182 shares of the company’s stock worth $300,000 after acquiring an additional 184 shares in the last quarter. 79.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth LNT has been the subject of a number of analyst reports. Scotiabank restated a “sector perform” rating and issued a $74.00 price target (up from $72.00) on shares of Alliant Energy in a report on Monday, May 4th. BMO Capital Markets reissued an “outperform” rating and set a $83.00 target price (up from $81.00) on shares of Alliant Energy in a research report on Wednesday, July 15th. Mizuho set a $76.00 target price on shares of Alliant Energy in a research note on Monday, May 4th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $76.00 price target on shares of Alliant Energy in a report on Tuesday, April 21st. Finally, Weiss Ratings raised shares of Alliant Energy from a “buy (b)” rating to a “buy (b+)” rating in a research note on Tuesday, July 7th. Nine equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Alliant Energy has a consensus rating of “Moderate Buy” and an average price target of $77.36.

View Our Latest Stock Analysis on Alliant Energy

Alliant Energy Price Performance Shares of NASDAQ LNT opened at $73.11 on Wednesday. The company has a quick ratio of 0.53, a current ratio of 0.69 and a debt-to-equity ratio of 1.48. Alliant Energy Corporation has a fifty-two week low of $63.28 and a fifty-two week high of $78.81. The business has a 50 day moving average price of $74.00 and a two-hundred day moving average price of $71.42. The firm has a market cap of $18.88 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 3.02 and a beta of 0.55.

Alliant Energy (NASDAQ:LNT – Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $0.82 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.82. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.08 billion. Alliant Energy had a return on equity of 11.37% and a net margin of 18.58%.Alliant Energy’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.83 EPS. Alliant Energy has set its FY 2026 guidance at 3.360-3.460 EPS. Sell-side analysts expect that Alliant Energy Corporation will post 3.43 earnings per share for the current fiscal year.

Alliant Energy Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Friday, July 31st will be paid a dividend of $0.535 per share. This represents a $2.14 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, July 31st. Alliant Energy’s dividend payout ratio is 67.08%.

Alliant Energy Company Profile (Free Report)

Alliant Energy Corporation (NASDAQ: LNT) is a publicly traded energy holding company headquartered in Madison, Wisconsin, that provides regulated electric and natural gas utility services in the American Midwest. The company serves customers primarily in Wisconsin and Iowa through its regulated utility subsidiaries and operates as an integrated provider responsible for generation, transmission and distribution of energy to residential, commercial and industrial customers.

Alliant Energy’s core activities include operating and maintaining electric generation assets, managing the regional transmission and distribution network, and delivering natural gas service to its franchise territories.

Featured Articles Five stocks we like better than Alliant Energy Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Alliant Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliant Energy and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Acquires 50,289 Shares of Kimco Realty Corporation $KIM

NEXT HEADLINE »California Public Employees Retirement System Has $29.32 Million Stock Holdings in Coeur Mining, Inc. $CDE

California Public Employees Retirement System lessened its holdings in shares of Rollins, Inc. (NYSE: ROL) by 11.9% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 645,835 shares of the business services provider's stock after selling 87,257 shares during the period. California Public Employees

Sameer to drive growth, investment in wealth management business

, /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) today announced Shimna Sameer as head of Truist Wealth. Sameer joins the company to accelerate the performance and scale the delivery of Truist's wealth management business.

As head of Truist Wealth, Sameer will have broad oversight of business strategy, including the delivery of Truist's purpose-driven wealth experience to clients, enhancing the advisor and client experience, investing in and deploying innovative technology, strengthening partnerships across the enterprise and delivering long-term growth.

Shimna Sameer announced head of Truist Wealth. Sameer has more than 20 years of experience in consumer banking, wealth management and private banking. Most recently, she served as head of products, solutions and platforms at Bank of America Private Bank. In this role, Sameer was responsible for managing the Private Bank's digital platforms, business and talent strategies and client experience, as well as driving business opportunities across the enterprise. She also led the delivery of the firm's specialized capabilities – including wealth strategy, trust services, custom lending and art services – to all of Bank of America's wealth management clients. Throughout her career, Sameer has led scaled client-facing businesses and large transformational initiatives, including developing the strategy for the sales organization, digital solutions and talent development for Merrill Edge.

Sameer will join Truist in October, reporting to Chief Wholesale Banking Officer Kristin Lesher, and serve as a member of the Truist Operating Council. She will be based in Truist's Hudson Yards offices in New York City.

"Truist Wealth is critical to our enterprise growth strategy and we'll continue to invest in technology enhancements, empower our advisors and broaden the solutions we provide clients," said Kristin Lesher, Truist Chief Wholesale Banking Officer. "Shim has spent her career serving clients, leading organizations to achieve outsized results and designing and implementing strategies that drive performance. She has a proven ability to partner across the enterprise, support advisor growth and development and leverage technology to scale businesses. Her experience and success across banking and wealth management will shape Truist Wealth at an important moment in our business."

Truist Wealth delivers holistic wealth management solutions to affluent, high, and ultra-high net worth individuals, families, and business owners across the U.S. and abroad. Truist Wealth is part of the Truist Wholesale Banking segment which provides comprehensive solutions to commercial, corporate, institutional and high-net-worth clients through a combination of regional coverage and industry-focused teams serving clients across the U.S.

About Truist

Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $556 billion as of June 30, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

About Truist Wealth

Truist Wealth delivers holistic wealth management solutions to affluent, high, and ultra-high net worth individuals, families, and business owners across the U.S. and abroad. Truist Wealth provides distinct solutions for individuals and businesses through the following affiliates: Banking products and services, corporate trust, escrow, and institutional investment management services to public, private, and nonprofit organizations provided by Truist Bank, Member FDIC. Securities, brokerage accounts, and/or annuities offered by Truist Investment Services, Inc., member FINRA, SIPC, and a licensed insurance agency. Investment advisory services offered by Truist Advisory Services, Inc. and affiliated SEC registered investment advisers.

SOURCE Truist Financial Corporation

Americké futures kontrakty ztrácejí

July 22, 2026 08:00 ET  | Source: LB Pharmaceuticals Inc

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027. NOVA-2 is a pivotal Phase 3 multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of LB-102 for the treatment of schizophrenia. The trial is designed to enroll approximately 460 patients across 25 sites in the U.S. 

“Enrollment in our pivotal Phase 3 NOVA-2 trial has been more rapid than we expected, which we believe is a reflection of both the strength of our execution and the level of interest in LB-102 as a potential new treatment for schizophrenia. Based on the pace of enrollment since initiating NOVA-2, we now expect to report topline results in the first half of 2027, ahead of our prior guidance of the second half of 2027, and to schedule a pre-NDA meeting soon thereafter in the second half of 2027,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “We remain well capitalized with a cash runway expected to fund operations into the second quarter of 2029 through multiple clinical readouts, with topline data from the Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression expected in the first quarter of 2028, and from the Phase 2 trial of LB-102 in adjunctive MDD in the first half of 2029.”

About LB-102

LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the United States for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the United States, LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT-7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to address multiple dimensions of neuropsychiatric illness. The pivotal Phase 3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a Phase 2 trial of LB-102 in adjunctive treatment of MDD is planned. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases. 

About LB Pharmaceuticals

LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102; the design, objectives, initiation, timing, progress and results of clinical trials of LB-102, including the pivotal Phase 3 NOVA-2 trial in acute schizophrenia, our open label trial (NOVA-3), the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression and the Phase 2 trial for the adjunctive treatment of MDD; and anticipated cash runway into the second quarter of 2029. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media and Investor Contact: 
Ellen Rose
[email protected]

Posted by Defense World Staff on Jul 22nd, 2026

Arvest Bank Trust Division lessened its position in O’Reilly Automotive, Inc. (NASDAQ:ORLY – Free Report) by 42.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,357 shares of the specialty retailer’s stock after selling 7,786 shares during the period. Arvest Bank Trust Division’s holdings in O’Reilly Automotive were worth $956,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in O’Reilly Automotive by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 79,730,143 shares of the specialty retailer’s stock valued at $7,272,186,000 after buying an additional 458,613 shares in the last quarter. State Street Corp increased its position in shares of O’Reilly Automotive by 0.4% in the fourth quarter. State Street Corp now owns 37,206,098 shares of the specialty retailer’s stock valued at $3,393,568,000 after acquiring an additional 140,387 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of O’Reilly Automotive by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 24,140,497 shares of the specialty retailer’s stock worth $2,201,555,000 after purchasing an additional 372,896 shares in the last quarter. Wellington Management Group LLP lifted its stake in O’Reilly Automotive by 25.1% in the fourth quarter. Wellington Management Group LLP now owns 14,755,276 shares of the specialty retailer’s stock valued at $1,345,829,000 after acquiring an additional 2,964,945 shares during the last quarter. Finally, Norges Bank acquired a new stake in O’Reilly Automotive in the 4th quarter valued at about $1,134,311,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analyst Upgrades and Downgrades A number of equities analysts have commented on the stock. Citigroup reaffirmed a “buy” rating and set a $115.00 price objective (up from $110.00) on shares of O’Reilly Automotive in a research report on Friday, May 1st. Raymond James Financial reaffirmed an “outperform” rating and issued a $115.00 price objective on shares of O’Reilly Automotive in a report on Friday, May 1st. Wolfe Research set a $98.00 price target on shares of O’Reilly Automotive in a report on Wednesday, July 15th. Mizuho raised their price objective on O’Reilly Automotive from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, Robert W. Baird set a $110.00 target price on shares of O’Reilly Automotive in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, O’Reilly Automotive has an average rating of “Moderate Buy” and an average target price of $110.70.

Get Our Latest Research Report on ORLY

O’Reilly Automotive Price Performance Shares of O’Reilly Automotive stock opened at $87.97 on Wednesday. The firm has a market cap of $72.90 billion, a price-to-earnings ratio of 28.75, a PEG ratio of 1.86 and a beta of 0.51. O’Reilly Automotive, Inc. has a one year low of $82.59 and a one year high of $108.71. The stock’s 50-day moving average is $88.55 and its 200 day moving average is $91.83.

O’Reilly Automotive (NASDAQ:ORLY – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The specialty retailer reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.03. The company had revenue of $4.56 billion during the quarter, compared to analyst estimates of $4.46 billion. O’Reilly Automotive had a net margin of 14.30% and a negative return on equity of 263.22%. O’Reilly Automotive’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $9.35 EPS. O’Reilly Automotive has set its FY 2026 guidance at 3.150-3.250 EPS. On average, sell-side analysts expect that O’Reilly Automotive, Inc. will post 3.24 EPS for the current fiscal year.

Insider Activity In related news, CEO Brad W. Beckham sold 13,635 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $95.00, for a total value of $1,295,325.00. Following the transaction, the chief executive officer directly owned 12,250 shares in the company, valued at $1,163,750. This trade represents a 52.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Philip M. Hopper sold 3,700 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $94.60, for a total transaction of $350,020.00. Following the transaction, the senior vice president owned 4,888 shares in the company, valued at approximately $462,404.80. The trade was a 43.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 105,730 shares of company stock valued at $9,815,388. Corporate insiders own 0.77% of the company’s stock.

About O’Reilly Automotive (Free Report)

O’Reilly Automotive, Inc is a leading retailer and distributor in the automotive aftermarket, supplying parts, tools, supplies and accessories for both professional service providers and do‑it‑yourself (DIY) customers. The company’s product assortment covers replacement parts, maintenance items, performance parts, collision components and shop equipment, complemented by diagnostic tools, batteries, chemicals and consumables. O’Reilly serves customers through company-operated retail stores, commercial sales programs for repair shops and maintenance fleets, and digital channels that support parts lookup, ordering and fulfillment.

The company operates a broad supply chain that includes regional distribution centers to support rapid replenishment of store inventory and commercial deliveries.

Featured Articles Five stocks we like better than O’Reilly Automotive Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for O'Reilly Automotive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for O'Reilly Automotive and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAcumen Wealth Advisors LLC Reduces Stock Holdings in ASML Holding N.V. $ASML

Andra AP fonden grew its holdings in shares of Marvell Technology, Inc. (NASDAQ:MRVL – Free Report) by 1,800.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 162,907 shares of the semiconductor company’s stock after purchasing an additional 154,335 shares during the quarter. Andra AP fonden’s holdings in Marvell Technology were worth $16,136,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of MRVL. State Street Corp lifted its stake in shares of Marvell Technology by 7.9% in the fourth quarter. State Street Corp now owns 22,834,816 shares of the semiconductor company’s stock worth $1,940,503,000 after buying an additional 1,677,724 shares in the last quarter. Geode Capital Management LLC grew its stake in Marvell Technology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 12,108,452 shares of the semiconductor company’s stock valued at $1,025,185,000 after acquiring an additional 97,624 shares in the last quarter. Norges Bank purchased a new stake in Marvell Technology during the 4th quarter valued at about $895,455,000. Van ECK Associates Corp raised its holdings in Marvell Technology by 11.4% in the 4th quarter. Van ECK Associates Corp now owns 9,864,514 shares of the semiconductor company’s stock valued at $838,286,000 after acquiring an additional 1,007,315 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Marvell Technology by 9.7% in the 4th quarter. Northern Trust Corp now owns 6,798,272 shares of the semiconductor company’s stock worth $577,717,000 after purchasing an additional 598,920 shares in the last quarter. Hedge funds and other institutional investors own 83.51% of the company’s stock.

Wall Street Analyst Weigh In A number of equities analysts have weighed in on the company. Jefferies Financial Group boosted their price objective on Marvell Technology from $149.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Melius Research set a $220.00 price target on Marvell Technology in a research report on Monday, May 18th. Loop Capital raised Marvell Technology to a “strong-buy” rating in a research report on Tuesday, June 16th. Raymond James Financial set a $235.00 price target on Marvell Technology and gave the stock a “strong-buy” rating in a report on Thursday, May 28th. Finally, Stifel Nicolaus raised their price target on Marvell Technology from $321.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-seven have issued a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $245.45.

Check Out Our Latest Research Report on Marvell Technology

Insider Activity In related news, CEO Matthew J. Murphy sold 7,500 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $177.26, for a total value of $1,329,450.00. Following the completion of the transaction, the chief executive officer owned 739,397 shares of the company’s stock, valued at approximately $131,065,512.22. The trade was a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sandeep Bharathi sold 2,231 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $299.13, for a total transaction of $667,359.03. Following the completion of the transaction, the insider owned 55,530 shares in the company, valued at approximately $16,610,688.90. This trade represents a 3.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 45,981 shares of company stock worth $9,835,542 in the last quarter. Corporate insiders own 0.12% of the company’s stock.

Marvell Technology Stock Performance Shares of MRVL stock opened at $207.96 on Wednesday. The stock has a market cap of $181.92 billion, a PE ratio of 71.22, a P/E/G ratio of 1.28 and a beta of 2.20. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.66 and a current ratio of 3.28. Marvell Technology, Inc. has a 1 year low of $61.44 and a 1 year high of $329.88. The stock has a fifty day moving average price of $241.88 and a 200 day moving average price of $151.14.

Marvell Technology (NASDAQ:MRVL – Get Free Report) last released its quarterly earnings data on Wednesday, May 27th. The semiconductor company reported $0.80 EPS for the quarter, hitting the consensus estimate of $0.80. The business had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.41 billion. Marvell Technology had a net margin of 28.99% and a return on equity of 13.83%. The business’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.62 EPS. Marvell Technology has set its Q2 2027 guidance at 0.880-0.980 EPS. Sell-side analysts forecast that Marvell Technology, Inc. will post 3.07 earnings per share for the current fiscal year.

Marvell Technology Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 30th. Stockholders of record on Friday, July 10th will be given a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 0.1%. The ex-dividend date is Friday, July 10th. Marvell Technology’s dividend payout ratio is currently 8.22%.

More Marvell Technology News Here are the key news stories impacting Marvell Technology this week:

Positive Sentiment: Marvell is benefiting from renewed enthusiasm for AI infrastructure spending, which lifted semiconductor stocks across the market and helped chip names like MRVL rally. Marvell Stock Jumps As AI Infrastructure Spending Boom Powers Semiconductor Rally Positive Sentiment: Market coverage highlighted Marvell among the chip leaders powering a Nasdaq rebound, with investors buying back into memory and AI-related semiconductor stocks after recent weakness. Stock Market Today: Nasdaq Higher As Memory Chip Names Rally; Schwab Slides (Live Coverage) Positive Sentiment: Analysts and media pieces pointed to Marvell’s strong first-half performance and improving growth profile, reinforcing the view that the stock remains a key AI infrastructure play. Why Marvell Jumped 251% in the First Half of the Year Neutral Sentiment: Several commentary pieces noted that Marvell’s valuation has become a renewed topic of debate, suggesting the rally may face scrutiny if growth expectations cool. Marvell Technology (MRVL) Rises With AI Chip Rally As Valuation Questions Return Negative Sentiment: Some articles reminded investors that Marvell is still well below its recent highs, with caution that the stock’s earlier AI-driven surge may have outpaced fundamentals. Marvell Technology: The Stock Is Down 39% From Its High. Time to Buy the Dip? About Marvell Technology (Free Report)

Marvell Technology Group is a global semiconductor company that designs and develops integrated circuits and related software for data infrastructure, networking, storage and connectivity markets. The company’s product portfolio includes system-on-chip (SoC) solutions, Ethernet physical-layer transceivers (PHYs), switch and switch silicon, optical interconnect components, storage controllers, and security processors. Marvell’s technology is used to enable high-performance data centers, carrier networks, enterprise and cloud storage, as well as connectivity in automotive and industrial applications.

Founded in 1995 and headquartered in Santa Clara, California, Marvell has grown through both organic development and strategic acquisitions to broaden its capabilities across networking and data interconnect.

See Also Five stocks we like better than Marvell Technology Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding MRVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marvell Technology, Inc. (NASDAQ:MRVL – Free Report).

Receive News & Ratings for Marvell Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marvell Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Since 2007, Monster Beverage Corporation (MNST) rises1,668% due to outlier inflows.

MNST develops, markets, distributes, and sells 11 different brands of drinks and concentrates, including its namesake Monster Energy brand. MNST’s first-quarter fiscal 2026 report showed quarterly net sales of $2.35 billion (a 26.9% rise), double-digit growth in all regions, net income per diluted share of $0.58 (a 27.6% rise), as well as returning $100 million to shareholders through repurchases. The company reports again on July 30.

It’s no wonder MNST shares are up 23% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock

Institutions Thirsty for Monster Beverage Institutional volumes reveal plenty. Over the last year, MNST has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in MNST shares. They reflect our proprietary inflow signal, pushing the stock higher:

MNST garnered many institutional inflows over the course of a year versus just two outflows, pushing shares up 59%. Source: www.moneyflows.com Plenty of staples names are under accumulation right now. But there’s a powerful fundamental story happening with Monster Beverage.

Monster Beverage Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, MNST has had strong sales and earnings growth:

3-year sales growth rate (+9.6%) 3-year earnings growth rate (+21.4%) Source: FactSet

Also, EPS is estimated to ramp higher this year by +13.1%.

Now it makes sense why the stock has been powering to new heights. MNST has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Monster Beverage has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Outlier 20 report 92 times since 2007, gaining 1,668%. The blue bars below show when MNST was a top pick in the last year…institutional support drives prices higher:

A total of 14 outlier inflows from institutional investors in the last year pushed prices higher – MNST has 92 total outlier inflows and no outflows since 2007. Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Monster Beverage Price Prediction The MNST rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in MNST at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MoneyFlows process here.

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Author of the CMO Insider newsletter

Hershey is leaning into the "trunk or treat" trend, which often takes place long before Halloween. Hershey Stacy Taffet, Hershey's chief growth and marketing officer, has already entered her spooky season.

The Reese's and Jolly Rancher parent is conjuring up a new Halloween playbook, carving the holiday into distinct micro-seasons that start months before October 31, Taffet exclusively told CMO Insider.

A Morning Consult survey commissioned by Hershey in July found that 67% of US parents had bought Halloween candy or snacks during the summer in recent years. Almost half (49%) of parents polled were familiar with the term "Summerween."

With consumers celebrating Halloween early, CMOs face a challenge in building excitement without peaking too soon.

Taffet said Hershey has shifted from treating Halloween as "one long extended season" to a more occasion-led approach, with different brands and products promoted at different points.

Summer is about cueing the season with Reese's assorted Halloween shapes and marketing that centers on rituals like pumpkin carving and fall lattes.

"We'll use more parts of the portfolio that are either for individual consumption or for sharing in small groups as a way to say, 'Let's get excited, the season's coming,'" Taffet said.

As fall approaches, Hershey plans to lean into the "trunk or treating" trend, where families gather in parking lots for children to collect candy from car trunks.

When October nears, activity will ramp up, including a partnership with Amazon to deliver ready-to-go large trick-or-treat bowls and a bigger push for non-chocolate brands, such as its Pirate's Booty salty snacks.

Halloween is a high-stakes moment for Hershey. Last year, Hershey CEO Kirk Tanner said its Halloween sales performance had been disappointing, citing warmer weather among other factors. Retailers were also discounting candy at the time, following price hikes driven by higher cocoa prices.

Tanner said on last October's earnings call that there were opportunities to "go to school" on consumer insights to improve for Halloween 2026, such as evaluating new pack types, price points, and the product mix.

Behind the scenes, Taffet, who joined the company in April 2025, has been reconfiguring her department to handle moments like these.

"The biggest thing I've been focused on is really breaking down functional silos," so the company can more quickly react to consumer trends, Taffet said.

Within the growth office, the marketing, insights, innovation, and research and development teams now function together.

Hershey recently introduced a new marketing mix model — a method that determines the impact of individual marketing channels on sales — enabled by AI.

Taffet said AI and automation tools are making it easier for Hershey to flag celebrities and influencers who are already talking about its brands and reach out about potential partnerships. It has also deployed AI tools to its retail sales force to strengthen merchandising.

"Our retail team will go to a store manager and, using an augmented reality tool and analytics powered by AI, say, 'If you put the KitKat display over here by the checkout, your sales are going to go up by X%,'" Taffet said.

Taffet said Hershey is also aware that many people are financially stretched, and is introducing new product formats at lower prices.

"If they only have $20 to spend on getting their kid excited about Halloween, it could be a costume, it could be decorations, it could be Reese's Shapes, and we want to make sure that we're top of mind to delight people in that season," she said.

Read next

Lara O'Reilly You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Lara O'Reilly is the anchor of the CMO Insider newsletter.She is a senior correspondent who has covered the digital advertising, marketing, and media industries since 2010. Her current beat includes big tech companies like Alphabet, and Meta, and adtech firms, agencies,  publishers, the creator economy, and CMOs.Lara has previously worked as a reporter and executive producer at titles including The Wall Street Journal, Digiday, Yahoo Finance, and Marketing Week. She was previously Business Insider's senior global advertising editor from 2014 to 2017.Lara was named "Digital Journalist of the Year" by the London Press Club in 2016.Lara is a regular guest on TV and radio and has appeared on outlets such as the BBC, NPR, SiriusXM's Wharton Business Daily, and CTV Television Network. She also frequently speaks on stage at major events such as Web Summit, IFA, VivaTech, Advertising Week, and Cannes Lions.To get in touch with Lara O'Reilly, email [email protected] or contact her on Signal at @loreilly.71Check out Insider's source guide for tips on sharing information securely.Read some of Lara's recent work below:

Inside Amazon's plan to clobber rivals The Trade Desk and Google in a key area of advertisingMeet Cindy Rose, the former lawyer and top Microsoft exec set to become CEO of ad giant WPPHow X CEO Linda Yaccarino went from Elon Musk's fixer to out of a job in 2 yearsInside the political reckoning shaking up the ad industryMeet the 'reclusive' tech billionaire making an audacious bid to buy TikTokTop marketers are under a ton of pressure. They told me how they're trying to make themselves recession-proof.Big Tech workers got too used to perks. The pampering is over. Halloween

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG), a condition that significantly increases the risk of acute pancreatitis (AP), which is associated with repeated hospital admissions and can be fatal. SHASTA-3 and SHASTA-4 successfully met the primary endpoint of triglyceride reduction versus placebo and m.

Posted by Defense World Staff on Jul 22nd, 2026

D.A. Davidson & CO. grew its holdings in Toast, Inc. (NYSE:TOST – Free Report) by 52.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 72,079 shares of the company’s stock after buying an additional 24,868 shares during the quarter. D.A. Davidson & CO.’s holdings in Toast were worth $1,911,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Bayban bought a new position in shares of Toast during the fourth quarter valued at approximately $25,000. SHP Wealth Management purchased a new position in shares of Toast in the fourth quarter worth approximately $29,000. Strive Financial Group LLC purchased a new position in shares of Toast during the 4th quarter worth $29,000. Central Pacific Bank Trust Division grew its stake in shares of Toast by 123.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 943 shares of the company’s stock valued at $33,000 after acquiring an additional 521 shares during the period. Finally, Silicon Valley Capital Partners purchased a new stake in shares of Toast in the fourth quarter worth $36,000. Institutional investors own 82.91% of the company’s stock.

Wall Street Analysts Forecast Growth A number of equities analysts recently weighed in on the stock. Morgan Stanley set a $45.00 target price on shares of Toast in a research report on Friday, May 8th. UBS Group decreased their price objective on Toast from $40.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Barclays began coverage on shares of Toast in a research note on Tuesday, July 7th. They issued an “overweight” rating and a $35.00 target price on the stock. Citigroup cut their price objective on Toast from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Robert W. Baird lifted their price target on shares of Toast from $30.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.96.

View Our Latest Report on TOST

Toast Trading Down 1.5% NYSE:TOST opened at $30.40 on Wednesday. The firm has a fifty day simple moving average of $26.19 and a 200-day simple moving average of $28.12. Toast, Inc. has a 12 month low of $22.26 and a 12 month high of $49.66. The company has a market capitalization of $15.69 billion, a P/E ratio of 46.77 and a beta of 1.74.

Toast (NYSE:TOST – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.08). Toast had a net margin of 6.39% and a return on equity of 20.86%. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.63 billion. During the same quarter in the previous year, the firm posted $0.09 EPS. The firm’s revenue for the quarter was up 21.9% compared to the same quarter last year. Equities analysts forecast that Toast, Inc. will post 0.97 EPS for the current year.

Insider Buying and Selling In related news, CEO Aman Narang sold 14,365 shares of Toast stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $28.85, for a total transaction of $414,430.25. Following the completion of the transaction, the chief executive officer directly owned 70,451 shares in the company, valued at approximately $2,032,511.35. This trade represents a 16.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CRO Jonathan Vassil sold 3,150 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $30.03, for a total transaction of $94,594.50. Following the completion of the transaction, the executive owned 69,966 shares of the company’s stock, valued at approximately $2,101,078.98. This represents a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 159,265 shares of company stock valued at $4,278,832 in the last 90 days. 10.03% of the stock is currently owned by insiders.

Toast Company Profile (Free Report)

Toast, Inc (NYSE: TOST) is a technology company that builds a cloud-based platform for restaurants and other foodservice businesses. Headquartered in Boston, Massachusetts, Toast offers integrated point-of-sale (POS) systems and a suite of software and hardware designed to streamline front-of-house and back-of-house operations. The company went public in 2021 and has positioned itself as a vertically integrated provider for the restaurant industry.

Toast’s product portfolio includes touchscreen POS terminals and handheld order-and-pay devices, kitchen display systems, and peripherals tailored for high-volume foodservice environments.

See Also Five stocks we like better than Toast Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding TOST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Toast, Inc. (NYSE:TOST – Free Report).

Receive News & Ratings for Toast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Toast and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINED.A. Davidson & CO. Has $1.89 Million Position in Amcor PLC $AMCR

NEXT HEADLINE »Bank of New York Mellon Corp Sells 255,274 Shares of Tyler Technologies, Inc. $TYL

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Teledyne Technologies Incorporated (NYSE:TDY) All time record quarterly orders, sales and operating profit Second quarter net sales of $1,662.5 million, an increase of 9.8% compared with last year Second quarter GAAP diluted earnings per share of $5.37 Second quarter non-GAAP diluted earnings per share of $6.28, an increase of 20.8% compared with last year Second quarter cash from operations of $315.2 million and free cash flow of $284.7 million Raising f.

6.96K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The home builder posted a profit of $472 million, or $2.48 a share, compared with $608 million, or $3.03 a share, in the same quarter a year earlier.

ABN Amro Investment Solutions trimmed its position in shares of Quanta Services, Inc. (NYSE:PWR – Free Report) by 6.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,353 shares of the construction company’s stock after selling 3,106 shares during the quarter. ABN Amro Investment Solutions’ holdings in Quanta Services were worth $25,998,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC bought a new stake in shares of Quanta Services in the 4th quarter worth about $298,000. Woodline Partners LP raised its position in Quanta Services by 40.7% in the 1st quarter. Woodline Partners LP now owns 12,471 shares of the construction company’s stock worth $3,170,000 after purchasing an additional 3,606 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in Quanta Services in the second quarter worth about $4,632,000. Marshall Wace LLP purchased a new position in shares of Quanta Services during the second quarter valued at approximately $996,000. Finally, StoneX Group Inc. bought a new position in shares of Quanta Services during the second quarter valued at approximately $204,000. Hedge funds and other institutional investors own 90.49% of the company’s stock.

Quanta Services Price Performance PWR opened at $638.74 on Wednesday. The company has a market capitalization of $95.85 billion, a price-to-earnings ratio of 87.62, a PEG ratio of 2.49 and a beta of 1.21. The company has a current ratio of 1.14, a quick ratio of 1.09 and a debt-to-equity ratio of 0.57. Quanta Services, Inc. has a 12-month low of $363.01 and a 12-month high of $788.75. The business’s fifty day simple moving average is $698.00 and its 200-day simple moving average is $602.38.

Quanta Services (NYSE:PWR – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The construction company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.64. Quanta Services had a return on equity of 18.64% and a net margin of 3.67%.The firm had revenue of $7.87 billion during the quarter, compared to the consensus estimate of $7 billion. During the same period in the previous year, the company posted $1.78 earnings per share. The firm’s quarterly revenue was up 26.3% on a year-over-year basis. Quanta Services has set its FY 2026 guidance at 13.550-14.250 EPS. On average, equities research analysts anticipate that Quanta Services, Inc. will post 12.8 earnings per share for the current fiscal year.

Quanta Services Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Monday, July 13th. Stockholders of record on Wednesday, July 1st were given a $0.11 dividend. This represents a $0.44 annualized dividend and a dividend yield of 0.1%. The ex-dividend date of this dividend was Wednesday, July 1st. Quanta Services’s dividend payout ratio is presently 6.04%.

Quanta Services announced that its board has authorized a share buyback program on Friday, May 22nd that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the construction company to buy up to 0.9% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In A number of equities research analysts recently issued reports on PWR shares. UBS Group raised their price target on Quanta Services from $646.00 to $900.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. B. Riley Financial reiterated a “neutral” rating on shares of Quanta Services in a research note on Friday, May 1st. Zacks Research lowered shares of Quanta Services from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Truist Financial upped their price target on shares of Quanta Services from $851.00 to $940.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Finally, CICC Research began coverage on shares of Quanta Services in a research note on Thursday, May 21st. They issued an “outperform” rating and a $872.00 price target on the stock. Seventeen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Quanta Services currently has a consensus rating of “Moderate Buy” and an average price target of $745.55.

Check Out Our Latest Research Report on PWR

Insider Activity at Quanta Services In other Quanta Services news, CAO Paul Nobel sold 4,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $756.98, for a total transaction of $3,027,920.00. Following the completion of the sale, the chief accounting officer owned 8,080 shares in the company, valued at $6,116,398.40. This represents a 33.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Earl C. Jr. Austin sold 25,992 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $770.71, for a total value of $20,032,294.32. Following the sale, the chief executive officer owned 16,508 shares of the company’s stock, valued at $12,722,880.68. This trade represents a 61.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 159,992 shares of company stock valued at $123,244,714 in the last ninety days. Corporate insiders own 0.60% of the company’s stock.

Key Stories Impacting Quanta Services Here are the key news stories impacting Quanta Services this week:

Positive Sentiment: Quanta was named the 2026 Top U.S. Solar Solutions Provider by Solar Power World for the third time in four years, highlighting its leadership in solar project execution and its ability to win large renewable-energy contracts. Quanta Services Named 2026 Top U.S. Solar Solutions Provider by Solar Power World Positive Sentiment: Analysts and investors are pointing to Quanta’s execution certainty as a competitive advantage, especially as utilities and technology customers ramp up spending on large, complex infrastructure projects. Can Quanta’s Execution Certainty Strengthen Its Competitive Position? Positive Sentiment: JPMorgan reaffirmed a Neutral rating but set a $714 price target, which is above the current share price and suggests upside if execution remains strong. JPMorgan rating update via Benzinga Neutral Sentiment: Market commentary noted that PWR has outpaced the broader market in the latest session, reflecting continued investor interest but not a new fundamental catalyst. Quanta Services (PWR) Outpaces Stock Market Gains: What You Should Know Neutral Sentiment: One article argued the stock may look pricey on cash flow and earnings, which could limit near-term upside if valuation concerns gain traction. Quanta Services (PWR) Stock Looks Pricey On Cash Flow And Earnings Neutral Sentiment: NZS Capital said it strengthened its position in Quanta in a quarterly letter, but the note was broader portfolio commentary rather than a company-specific catalyst. NZS Capital Quanta Services position update Quanta Services Profile (Free Report)

Quanta Services, Inc is a leading specialty contractor that provides comprehensive infrastructure solutions for the electric power, pipeline and energy, and communications markets. Headquartered in Houston, Texas, the company delivers engineering, procurement, construction, installation, maintenance and repair services that support the development, modernization and ongoing operation of critical energy and communications networks.

In the electric power sector, Quanta works on transmission and distribution systems, substation construction and grid modernization projects that include integration of renewable generation and energy storage.

Featured Stories Five stocks we like better than Quanta Services Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Quanta Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanta Services and related companies with MarketBeat.com's FREE daily email newsletter.

EVANSVILLE, Ind., July 22, 2026 (GLOBE NEWSWIRE) -- Old National Bancorp (NASDAQ: ONB) reports 2Q26 net income applicable to common shares of $249.4 million, diluted EPS of $0.65; $250.4 million and $0.65 on an adjusted1 basis, respectively.

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 23.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,151 shares of the medical research company’s stock after selling 52,312 shares during the quarter. California Public Employees Retirement System owned about 0.12% of Natera worth $34,228,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Horizon Investments LLC increased its stake in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the period. Savvy Advisors Inc. boosted its holdings in shares of Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 46 shares in the last quarter. First Horizon Corp boosted its holdings in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 51 shares in the last quarter. Finally, Siemens Fonds Invest GmbH increased its stake in shares of Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Up 1.7% Shares of NTRA opened at $267.18 on Wednesday. The company has a 50-day simple moving average of $236.50 and a 200-day simple moving average of $220.83. The company has a market capitalization of $38.26 billion, a PE ratio of -163.91 and a beta of 1.51. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $288.04.

Wall Street Analyst Weigh In NTRA has been the subject of several analyst reports. Canaccord Genuity Group increased their price target on shares of Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Piper Sandler reiterated an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. UBS Group set a $260.00 target price on Natera in a research note on Wednesday, June 24th. Finally, Wolfe Research started coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Check Out Our Latest Analysis on NTRA

Insider Activity In other news, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00. Following the sale, the insider owned 134,643 shares of the company’s stock, valued at $36,744,074.70. The trade was a 2.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,872 shares of company stock valued at $39,627,696 in the last quarter. Insiders own 5.05% of the company’s stock.

About Natera (Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Featured Stories Five stocks we like better than Natera Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlesco Advisors LLC An ESL Co Invests $912,000 in BlackRock $BLK

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System lessened its position in shares of MongoDB, Inc. (NASDAQ:MDB – Free Report) by 2.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,197 shares of the company’s stock after selling 3,644 shares during the period. California Public Employees Retirement System owned approximately 0.16% of MongoDB worth $32,113,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MDB. Cornerstone Planning Group LLC lifted its stake in shares of MongoDB by 1,220.0% in the 4th quarter. Cornerstone Planning Group LLC now owns 66 shares of the company’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Central Pacific Bank Trust Division acquired a new stake in MongoDB during the 4th quarter worth approximately $28,000. International Assets Investment Management LLC acquired a new stake in MongoDB during the 4th quarter worth approximately $33,000. Root Financial Partners LLC raised its holdings in MongoDB by 58.2% in the fourth quarter. Root Financial Partners LLC now owns 87 shares of the company’s stock valued at $37,000 after buying an additional 32 shares during the period. Finally, Global Trust Asset Management LLC acquired a new position in MongoDB during the fourth quarter valued at approximately $38,000. 89.29% of the stock is currently owned by institutional investors and hedge funds.

MongoDB Trading Down 4.9% Shares of MDB stock opened at $307.65 on Wednesday. The company has a market capitalization of $24.74 billion, a PE ratio of -831.49, a price-to-earnings-growth ratio of 1,325.25 and a beta of 1.55. The firm has a fifty day simple moving average of $337.07 and a 200-day simple moving average of $321.91. MongoDB, Inc. has a twelve month low of $198.47 and a twelve month high of $444.72.

MongoDB (NASDAQ:MDB – Get Free Report) last released its quarterly earnings results on Thursday, May 28th. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.13. MongoDB had a negative net margin of 1.12% and a negative return on equity of 1.39%. The business had revenue of $687.62 million during the quarter, compared to analyst estimates of $664.53 million. During the same period last year, the business earned $1.00 EPS. The business’s revenue was up 25.2% on a year-over-year basis. MongoDB has set its FY 2027 guidance at 5.950-6.140 EPS and its Q2 2027 guidance at 1.580-1.610 EPS. Equities research analysts predict that MongoDB, Inc. will post 0.02 EPS for the current year.

Insider Activity at MongoDB In related news, CFO Michael J. Berry sold 5,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $356.63, for a total value of $1,783,150.00. Following the transaction, the chief financial officer owned 1,500 shares in the company, valued at approximately $534,945. The trade was a 76.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dev Ittycheria sold 40,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $383.16, for a total value of $15,326,400.00. Following the completion of the transaction, the director directly owned 161,762 shares of the company’s stock, valued at $61,980,727.92. This represents a 19.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 127,746 shares of company stock valued at $47,343,538. 2.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades MDB has been the subject of several recent research reports. DA Davidson reissued a “buy” rating and issued a $375.00 price objective on shares of MongoDB in a research report on Friday, May 29th. Piper Sandler lifted their target price on shares of MongoDB from $330.00 to $400.00 and gave the company an “overweight” rating in a report on Friday, May 29th. Mizuho upped their price target on shares of MongoDB from $325.00 to $400.00 and gave the stock an “outperform” rating in a research report on Friday, May 29th. KGI Securities initiated coverage on MongoDB in a report on Wednesday, July 8th. They issued an “outperform” rating and a $470.00 price target for the company. Finally, Robert W. Baird raised their price objective on MongoDB from $260.00 to $335.00 and gave the company a “neutral” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-seven have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, MongoDB presently has a consensus rating of “Moderate Buy” and an average target price of $405.35.

Get Our Latest Report on MDB

MongoDB Company Profile (Free Report)

MongoDB, Inc is a software company best known for developing MongoDB, a general-purpose, document-oriented database designed for modern application development. The company’s platform is built to support high-performance, scalable data storage and retrieval for use cases such as cloud-native applications, mobile backends, real-time analytics, and content management. MongoDB offers a mix of open-source software, commercial server distributions, and subscription-based services that include technical support, training and professional services.

The company traces its origins to 2007 when it was founded as 10gen by Dwight Merriman and Eliot Horowitz; it later adopted the MongoDB name and completed a public listing in 2017.

Featured Articles Five stocks we like better than MongoDB Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding MDB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MongoDB, Inc. (NASDAQ:MDB – Free Report).

Receive News & Ratings for MongoDB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MongoDB and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlphabet Inc. $GOOGL Shares Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

NEXT HEADLINE »Rollins, Inc. $ROL Shares Sold by California Public Employees Retirement System

TEMPE, Ariz.--(BUSINESS WIRE)--Dutch Bros Inc. (“Dutch Bros”) (NYSE: BROS), one of the fastest-growing brands in the U.S. quick service beverage industry, will host a conference call and webcast to review financial results for the second quarter, which ended on June 30, 2026. The conference call and webcast will take place on Wednesday, August 5, 2026 at 5:00 p.m. Eastern Time (ET). Dutch Bros will report financial results for the second quarter 2026 after the market close that same day. Event:.

The FIFA World Cup raked in massive viewership numbers for its media rights owners Fox Corp. and NBCUniversal's Telemundo.

But NBCUniversal executives say the big audience numbers for the World Cup didn't just reinforce the importance of live sports in an environment where media companies are competing harder than ever to draw viewers, they also highlighted that Spanish-language programming has become an important part of its strategy for streaming service Peacock.

The World Cup final broke records for both English and Spanish telecasts, according to Nielsen. Nearly 39 million viewers watched on Fox's broadcast and streaming outlets, while about 24 million tuned in on Telemundo, Peacock and other NBC properties, marking the most watched Spanish broadcast of a soccer match in the U.S. Telemundo and Peacock averaged 6.3 million viewers through the 104 matches.

Like other live sports, the event also raked in hefty advertising dollars. The tournament more than doubled revenue from 2022, the last time Telemundo and Peacock aired it, according to NBCUniversal chairman of global advertising and partnerships Mark Marshall.

It has also led to growth for Peacock's subscriber base and engagement, Marshall and Cesar Conde, who is the chairman of NBCUniversal News Group, including Telemundo, said in interviews.

"It not only brought so many new audiences and subscribers to Peacock, but it also introduced them to so much additional programming that they weren't familiar with," Conde said, adding that through Peacock viewers had different ways of consuming the content, from multiview to trivia offerings. "I think it made a big difference."

Peacock, which launched in 2020, had 46 million subscribers as of April 30 and is expected to hit profitability in the second quarter. Both of those metrics put the streaming service behind most of its competitors, including Netflix and Disney+.

Comcast, which announced on June 29 that it plans to spin off NBCUniversal, will report earnings results on Thursday.

Live sports in general have lifted Peacock — especially after NBCUniversal started airing the NBA in 2025. The growing presence of the Olympics on the platform has also been key, with all of the events now shown on Peacock, along with shoulder programming and other kinds of content.

Telemundo has also been bulking up on sports rights, in addition to offering NBC's sports in Spanish telecasts. This week Telemundo announced it had acquired the Spanish-language rights to the UEFA Champions League beginning with the 2027-28 season.

"In addition to just the big audiences, it also just showed us that consumers continue to change the way that they watch media," said Conde, referring to the World Cup. "We kind of knew that consumers were very fluid between linear and streaming. I think this also showed they are very fluid across language, and are looking for that authentic connection."

Peacock first aired the World Cup in Spanish in 2022, which provided a bigger-than-expected boost for the service. However, Peacock at the time was the main streaming outlet for the World Cup, regardless of language. This year Fox, the owner of the English-language rights, also offered the World Cup on its recently launched Fox One.

"I think it's a combination of the great work between both the Telemundo and the Peacock teams. The combination of that work allowed us to grab a huge share of that audience in streaming, despite having increased competition on that platform," Conde said.

FIFA is likely to sell the English and Spanish rights for the U.S. broadcast of the 2030 and 2034 World Cups combined in one package, rather than separately as it has in the past, CNBC recently reported.

"There seemed to be a lot of cannibalization in Spanish language for this World Cup," said Lee Berke, a sports media consultant and CEO of LHB Sports, Entertainment & Media. "You may as well sell the rights together, particularly when it's being offered on a stream basis. Then it's just a question of which feed the viewer is going to."

Each of the upcoming tournaments is expected to command between $1.5 billion and $2 billion, a big step up from the most recently negotiated deals, CNBC reported.

"This World Cup generated NFL style numbers, and if you could have aired those games, especially the Final, in prime time, it would have gotten closer to NFL championship numbers," Berke said.

Broader appeal of Spanish contentHowever, this added viewership from Spanish-language content has extended beyond sports, Marshall and Conde said, and advertisers are taking notice.

It's been a contributor to Peacock's growth, in particular.

"Sometimes we need events like this to reset how we think about marketing and consumers. We still have conversations where you have Spanish language as like a niche extension to a media plan," said Marshall regarding the World Cup. "The fact is this is a $4 trillion spending cohort that needs to be a centerpiece of your media plan, not an afterthought."

Advertising has become a more important revenue driver and business initiative for media companies. Two key reasons: increased pressure to make streaming services profitable outside of just subscriber fees and the skyrocketing costs of sports rights.

In response, advertisers are increasingly buying spots on Spanish-language content, especially as the Hispanic population has significantly grown in the U.S. Hispanic consumers make up about 20% of the U.S. population and represent more than $4.1 trillion in purchasing power, according to a 2025 report from Nielsen.

"Hispanic consumers are a powerful demographic for brands willing to meet them with authenticity and insight," said Stacie de Armas, Nielsen's head of inclusive content and insights.

Even outside of Spanish speakers, NBCUniversal is experimenting with getting English-language audiences to tune into Telemundo content.

The success of non-English-language series like Netflix's "Narcos" and "Squid Game," as well as the Korean film "Parasite," led NBCUniversal to test whether it could attract English-speaking audiences to Telemundo's content, particularly on Peacock.

Prior to the Season 10 premiere of "El Señor de los Cielos" on July 7, Telemundo and Peacock ran ads — in English and with English subtitles — pushing viewers to catch up on the prior seasons on Peacock.

As a result of the ad, viewership of prior "El Señor de los Cielos" seasons got a jolt: English-subtitle viewing was up 42% and English-dominant viewership jumped to 25% from 9%, said Marshall. New-to-Telemundo viewers for prior season of the show also rose to 39% from 22%.

"Now we're trying to see if there's other opportunities," to recreate this playbook for Telemundo and Peacock, Marshall said.

Posted by Defense World Staff on Jul 22nd, 2026

Fifth Third Bancorp lifted its holdings in shares of Albertsons Companies, Inc. (NYSE:ACI – Free Report) by 2,707.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,867 shares of the company’s stock after purchasing an additional 119,455 shares during the quarter. Fifth Third Bancorp’s holdings in Albertsons Companies were worth $2,111,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. CWM LLC increased its position in shares of Albertsons Companies by 103.5% during the fourth quarter. CWM LLC now owns 1,435 shares of the company’s stock valued at $25,000 after acquiring an additional 730 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Albertsons Companies by 185.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,628 shares of the company’s stock valued at $28,000 after acquiring an additional 1,057 shares during the period. NBC Securities Inc. lifted its holdings in shares of Albertsons Companies by 91.2% in the 4th quarter. NBC Securities Inc. now owns 1,855 shares of the company’s stock worth $32,000 after acquiring an additional 885 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Albertsons Companies by 172.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,062 shares of the company’s stock worth $35,000 after acquiring an additional 1,306 shares during the last quarter. Finally, Elevation Wealth Partners LLC purchased a new position in shares of Albertsons Companies during the 4th quarter worth approximately $46,000. 71.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In Several analysts recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Albertsons Companies from $21.00 to $18.00 and set an “overweight” rating for the company in a report on Monday, June 29th. Citigroup lowered their price target on Albertsons Companies from $22.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 29th. UBS Group dropped their price objective on Albertsons Companies from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Weiss Ratings downgraded Albertsons Companies from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $21.00 price objective on shares of Albertsons Companies in a report on Monday, April 6th. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $20.25.

Get Our Latest Stock Report on ACI

Albertsons Companies Trading Down 1.7% Shares of ACI stock opened at $14.70 on Wednesday. Albertsons Companies, Inc. has a fifty-two week low of $13.16 and a fifty-two week high of $20.91. The company has a 50 day moving average price of $15.08 and a 200 day moving average price of $16.45. The stock has a market capitalization of $7.20 billion, a P/E ratio of 45.94, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The company has a debt-to-equity ratio of 4.58, a quick ratio of 0.20 and a current ratio of 0.86.

Albertsons Companies Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Shareholders of record on Friday, July 24th will be paid a $0.17 dividend. The ex-dividend date is Friday, July 24th. This represents a $0.68 annualized dividend and a dividend yield of 4.6%. Albertsons Companies’s payout ratio is 212.50%.

Albertsons Companies Profile (Free Report)

Albertsons Companies, Inc (NYSE: ACI) is one of the largest food and drug retailers in the United States, operating a diversified portfolio of grocery store banners. Founded in 1939 by Joe Albertson in Boise, Idaho, the company has grown through both organic expansion and strategic acquisitions. Its core business activities encompass the sale of fresh produce, meat, bakery items, deli offerings, pharmacy services, and general merchandise. The company’s retail operations are complemented by an in-house private-label program, featuring brands such as O Organics, Open Nature, and Lucerne, which cater to a range of customer preferences and price points.

Throughout its history, Albertsons Companies has pursued growth via mergers and partnerships.

Featured Articles Five stocks we like better than Albertsons Companies Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Albertsons Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albertsons Companies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAcumen Wealth Advisors LLC Decreases Stock Position in UnitedHealth Group Incorporated $UNH

NEXT HEADLINE »ABN Amro Investment Solutions Decreases Stock Position in Quanta Services, Inc. $PWR

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System lowered its position in Pinnacle West Capital Corporation (NYSE:PNW – Free Report) by 13.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 275,327 shares of the utilities provider’s stock after selling 41,749 shares during the period. California Public Employees Retirement System owned about 0.23% of Pinnacle West Capital worth $27,739,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Kera Capital Partners Inc. lifted its holdings in Pinnacle West Capital by 13.4% in the first quarter. Kera Capital Partners Inc. now owns 4,535 shares of the utilities provider’s stock valued at $457,000 after acquiring an additional 537 shares during the period. Assetmark Inc. grew its stake in shares of Pinnacle West Capital by 32.8% during the 1st quarter. Assetmark Inc. now owns 1,719 shares of the utilities provider’s stock valued at $173,000 after purchasing an additional 425 shares during the period. NovaPoint Capital LLC grew its stake in shares of Pinnacle West Capital by 9.8% during the 1st quarter. NovaPoint Capital LLC now owns 13,741 shares of the utilities provider’s stock valued at $1,384,000 after purchasing an additional 1,222 shares during the period. Bessemer Group Inc. increased its position in shares of Pinnacle West Capital by 26.1% during the 1st quarter. Bessemer Group Inc. now owns 4,934 shares of the utilities provider’s stock valued at $496,000 after purchasing an additional 1,020 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Pinnacle West Capital by 1,510.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 115,939 shares of the utilities provider’s stock valued at $11,771,000 after purchasing an additional 108,742 shares during the last quarter. Hedge funds and other institutional investors own 91.51% of the company’s stock.

Pinnacle West Capital Stock Down 0.7% NYSE PNW opened at $105.61 on Wednesday. The stock’s 50-day moving average price is $104.01 and its 200-day moving average price is $100.19. The company has a quick ratio of 0.39, a current ratio of 0.60 and a debt-to-equity ratio of 1.38. Pinnacle West Capital Corporation has a 52 week low of $85.32 and a 52 week high of $111.16. The company has a market capitalization of $12.80 billion, a P/E ratio of 19.67, a price-to-earnings-growth ratio of 3.87 and a beta of 0.43.

Pinnacle West Capital (NYSE:PNW – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The utilities provider reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.30. The firm had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Pinnacle West Capital had a return on equity of 9.27% and a net margin of 11.99%.The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) EPS. Pinnacle West Capital has set its FY 2026 guidance at 4.550-4.750 EPS. On average, equities research analysts predict that Pinnacle West Capital Corporation will post 4.73 earnings per share for the current year.

Pinnacle West Capital Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, August 3rd will be given a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Monday, August 3rd. Pinnacle West Capital’s dividend payout ratio is presently 67.78%.

Insider Buying and Selling at Pinnacle West Capital In other news, EVP Jacob Tetlow sold 6,567 shares of the stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $99.00, for a total value of $650,133.00. Following the completion of the sale, the executive vice president directly owned 6,634 shares of the company’s stock, valued at $656,766. This represents a 49.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.19% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In Several brokerages have recently weighed in on PNW. Jefferies Financial Group reiterated a “buy” rating and issued a $129.00 price objective on shares of Pinnacle West Capital in a research note on Wednesday, July 8th. Argus boosted their target price on shares of Pinnacle West Capital from $95.00 to $106.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Wells Fargo & Company set a $106.00 target price on shares of Pinnacle West Capital in a report on Tuesday, April 21st. TD Cowen increased their price target on shares of Pinnacle West Capital from $100.00 to $101.00 and gave the stock a “hold” rating in a research report on Friday, May 15th. Finally, Truist Financial dropped their price target on shares of Pinnacle West Capital from $108.00 to $105.00 and set a “hold” rating on the stock in a research note on Friday, May 29th. Three research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $104.14.

Get Our Latest Stock Report on PNW

Pinnacle West Capital Profile (Free Report)

Pinnacle West Capital Corporation is a publicly traded utility holding company headquartered in Phoenix, Arizona. Through its principal subsidiary, Arizona Public Service Company (APS), Pinnacle West generates, transmits and distributes electricity to more than one million residential, commercial and industrial customers across central and southern Arizona. The company’s regulated operations focus on delivering safe, reliable power while meeting evolving environmental standards.

The company’s diversified generation portfolio includes natural gas–fired plants, the nuclear-powered Palo Verde Generating Station—the largest nuclear facility in the United States by net output—plus growing investments in solar and battery storage projects.

Featured Articles Five stocks we like better than Pinnacle West Capital Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Pinnacle West Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pinnacle West Capital and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDimensional Fund Advisors LP Raises Stock Holdings in PayPal Holdings, Inc. $PYPL

NEXT HEADLINE »California Public Employees Retirement System Sells 56,857 Shares of Equifax, Inc. $EFX

Posted by Defense World Staff on Jul 22nd, 2026

Andra AP fonden lifted its position in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 114.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,970 shares of the biopharmaceutical company’s stock after acquiring an additional 41,670 shares during the period. Andra AP fonden’s holdings in Insmed were worth $12,750,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its stake in shares of Insmed by 65.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 263 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Insmed by 80.8% during the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock valued at $4,770,000 after acquiring an additional 21,176 shares in the last quarter. Baird Financial Group Inc. bought a new stake in Insmed during the 2nd quarter worth $2,589,000. Amundi increased its holdings in Insmed by 21,194.4% in the 2nd quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock worth $1,130,000 after purchasing an additional 11,445 shares in the last quarter. Finally, Natixis acquired a new position in Insmed in the 2nd quarter worth about $1,072,000.

Wall Street Analyst Weigh In A number of brokerages have recently commented on INSM. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $166.00 to $212.00 in a research note on Monday, March 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Friday. Wells Fargo & Company raised their price objective on shares of Insmed from $160.00 to $161.00 and gave the company an “overweight” rating in a report on Wednesday, July 15th. Royal Bank Of Canada cut their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Finally, Guggenheim restated a “buy” rating and issued a $207.00 price target on shares of Insmed in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $209.13.

Get Our Latest Research Report on INSM

Insmed Stock Up 1.5% Shares of NASDAQ INSM opened at $108.62 on Wednesday. The company’s 50 day moving average price is $105.64 and its 200-day moving average price is $134.69. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The company has a market capitalization of $23.54 billion, a P/E ratio of -18.89 and a beta of 0.78.

Insmed (NASDAQ:INSM – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same period in the prior year, the company posted ($1.42) earnings per share. Insmed’s revenue for the quarter was up 229.7% compared to the same quarter last year. Equities analysts forecast that Insmed, Inc. will post -2.43 earnings per share for the current year.

Insiders Place Their Bets In related news, COO Roger Adsett sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $242,379.90. Following the completion of the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at $10,084,128.81. This trade represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the transaction, the chief executive officer owned 259,058 shares in the company, valued at $30,413,409.20. This represents a 3.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 54,590 shares of company stock worth $5,793,738 in the last quarter. 2.10% of the stock is currently owned by company insiders.

Insmed Profile (Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Further Reading Five stocks we like better than Insmed Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Trims Stock Position in Teck Resources Ltd $TECK

NEXT HEADLINE »Microsoft Corporation $MSFT Shares Sold by Capstone Wealth Management Group LLC

Posted by Defense World Staff on Jul 22nd, 2026

ABN Amro Investment Solutions acquired a new stake in shares of Trane Technologies plc (NYSE:TT – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 171,433 shares of the company’s stock, valued at approximately $71,443,000. Trane Technologies makes up approximately 0.9% of ABN Amro Investment Solutions’ portfolio, making the stock its 20th biggest holding. ABN Amro Investment Solutions owned about 0.08% of Trane Technologies as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Bell Investment Advisors Inc increased its position in shares of Trane Technologies by 12.2% in the 1st quarter. Bell Investment Advisors Inc now owns 203 shares of the company’s stock valued at $85,000 after acquiring an additional 22 shares during the period. Fiduciary Family Office LLC raised its stake in shares of Trane Technologies by 1.5% in the fourth quarter. Fiduciary Family Office LLC now owns 1,573 shares of the company’s stock worth $612,000 after purchasing an additional 23 shares during the last quarter. Foster Dykema Cabot & Partners LLC lifted its holdings in shares of Trane Technologies by 10.6% during the fourth quarter. Foster Dykema Cabot & Partners LLC now owns 239 shares of the company’s stock worth $93,000 after purchasing an additional 23 shares during the period. Bridges Investment Management Inc. lifted its holdings in shares of Trane Technologies by 1.6% during the fourth quarter. Bridges Investment Management Inc. now owns 1,542 shares of the company’s stock worth $600,000 after purchasing an additional 24 shares during the period. Finally, Cornerstone Planning Group LLC boosted its position in Trane Technologies by 14.5% in the first quarter. Cornerstone Planning Group LLC now owns 190 shares of the company’s stock valued at $79,000 after buying an additional 24 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth A number of equities analysts have issued reports on TT shares. Sanford C. Bernstein set a $555.00 price target on shares of Trane Technologies in a research report on Thursday, July 9th. BNP Paribas Exane initiated coverage on shares of Trane Technologies in a report on Tuesday, April 14th. They set an “outperform” rating and a $550.00 target price for the company. Barclays boosted their target price on shares of Trane Technologies from $507.00 to $585.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Trane Technologies in a research report on Friday. Finally, Royal Bank Of Canada lifted their price objective on Trane Technologies from $440.00 to $501.00 and gave the company a “sector perform” rating in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Trane Technologies has an average rating of “Moderate Buy” and a consensus target price of $516.67.

Get Our Latest Analysis on TT

Insider Activity at Trane Technologies In other news, insider Donald E. Simmons sold 4,593 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $500.00, for a total transaction of $2,296,500.00. Following the completion of the transaction, the insider directly owned 3,819 shares of the company’s stock, valued at $1,909,500. This represents a 54.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.43% of the stock is owned by company insiders.

Trane Technologies Trading Up 0.5% Shares of Trane Technologies stock opened at $470.42 on Wednesday. The firm has a 50-day simple moving average of $469.78 and a two-hundred day simple moving average of $448.47. The company has a market cap of $103.99 billion, a P/E ratio of 36.38, a price-to-earnings-growth ratio of 2.15 and a beta of 1.19. Trane Technologies plc has a fifty-two week low of $348.06 and a fifty-two week high of $505.87. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.10.

Trane Technologies (NYSE:TT – Get Free Report) last posted its earnings results on Friday, May 1st. The company reported $2.63 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.10. The firm had revenue of $4.97 billion for the quarter, compared to analysts’ expectations of $4.81 billion. Trane Technologies had a return on equity of 35.55% and a net margin of 13.41%.The company’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the firm earned $2.45 EPS. As a group, equities analysts predict that Trane Technologies plc will post 14.89 earnings per share for the current fiscal year.

Trane Technologies Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, September 4th will be given a $1.05 dividend. The ex-dividend date is Friday, September 4th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 0.9%. Trane Technologies’s payout ratio is 32.48%.

Trane Technologies Profile (Free Report)

Trane Technologies (NYSE: TT) is a global climate solutions company focused on heating, ventilation and air conditioning (HVAC) and transport refrigeration systems. The company develops, manufactures and sells a broad range of climate-control products under well-known brands, including commercial and residential HVAC equipment, building management systems and controls, and transport refrigeration units. Its product portfolio spans rooftop and packaged units, chillers, furnaces, air handlers, compressors, and related components designed for commercial buildings, industrial facilities, residences and transportation applications.

In addition to equipment, Trane Technologies provides lifecycle services that include installation, maintenance, parts, retrofit and aftermarket support, as well as digital and controls solutions for building performance and energy management.

Featured Stories Five stocks we like better than Trane Technologies Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Trane Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trane Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEArvest Bank Trust Division Boosts Stake in CVS Health Corporation $CVS

NEXT HEADLINE »Assetmark Inc. Sells 3,573 Shares of Reddit Inc. $RDDT

Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:

Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.i Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.ii Achieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,ii Outlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,ii , /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE: ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks1 faster2 than leading competitors Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).i

Newly Published Data Found Credelio Quattro:

Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. Faster2 Tick1 Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.i  Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ii Outperforms the Competition: Outperforms Simparica Trio® (12 hours) and NexGard® Plus (24 hours) at the end of the dosing period (Day 28).i Consistency Over Competitors: Achieves 8-hour speed of kill1 on Day 0 and on Day 28 with no performance drop-off. Rapid kill is critical for preventing Lyme disease transmission, which typically occurs 24-48 hours after attachment.i "Speed of kill is a critical factor for veterinarians and pet owners when choosing parasite coverage because the longer a tick is attached, the more likely it is to transmit dangerous diseases, like Lyme disease, to pets," said Dr. Casey Locklear, veterinarian and leading parasiticides expert at Elanco. "These results reinforce that lotilaner, the active ingredient in Credelio Quattro, not only starts working fast but maintains its speed of kill4 against multiple species of ticks5, providing veterinarians and pet owners with the confidence that their dogs are protected from the very start of the month to the very end."

The black-legged tick is the primary vector for Borrelia burgdorferi, the bacterium responsible for Lyme disease and anaplasmosis. The study, which evaluated the speed of kill against Ixodes scapularis (black-legged tick), found that Credelio Quattro was the only product tested to achieve significant initial tick reduction2 within just 8 hours of infestation. Notably, this rapid speed of kill1 was maintained from the beginning of the month through Day 28, providing consistent protection for the entire dosing interval.i

"Ticks are on the move. They are no longer limited to the places or seasons where we have historically expected to find them," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "As their geographic range expands, so does the risk of tick bites and exposure to the pathogens they carry. Because tick-borne diseases can threaten the health of people, pets, and livestock, raising public awareness is more important than ever as tick populations grow and spread into new regions."

The findings are based on evaluation time points at 4, 8, 12, 24, and 48 hours post-treatment and reinfestation. The data demonstrates that Credelio Quattro outperforms Simparica Trio and NexGard Plus in rapid tick1 reduction, particularly in the critical first 8 to 12 hours.i

Speed of kill against Ixodes scapularis (black-legged tick)^ i

Time point at which active achieved consistent superior efficacy vs. untreated control group¥ 

Day of Study 

Credelio Quattro

(lotilaner, moxidectin, praziquantel, and pyrantel)

Simparica Trio

(sarolaner, moxidectin and pyrantel)

NexGard Plus

(afoxolaner, moxidectin, and pyrantel)

0

8 hrs 

12 hrs 

12 hrs 

21

8 hrs 

24 hrs 

24 hrs 

28

8 hrs 

12 hrs 

24 hrs 

^Tick counts were evaluated at all 4-, 8-, 12-, 24-, and 48-hour time points as part of the study design 

¥P<0.05. 

Credelio Quattro also has a U.S. Food and Drug Administration approved claim for prevention of Lyme disease in dogs as a direct result of killing black-legged ticks.

Does Credelio Quattro Kill the Lone Star Tick?

Credelio Quattro is approved to protect dogs from the lone star tick (Amblyomma americanum), and its active ingredient, lotilaner, also has the fastest3 initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ii This aggressive and expanding tick species – established across the South, Midwest and Northeast, and continuing to spread –  is one of the hardest to kill and is best known for its association with alpha-gal syndrome, or the red meat allergy in humans. It can also transmit dangerous disease-causing pathogens to dogs.iii A 2024 head-to-head study published in Parasites & Vectors compared lotilaner, the active ingredient in Credelio (lotilaner) and Credelio Quattro with sarolaner in Simparica Trio and afoxolaner in NexGard®, and found that lotilaner kills the lone star tick faster4 than sarolaner in Simparica Trio and afoxolaner in NexGard, protecting dogs against this pathogen-carrying tick.  

Speed of kill against Amblyomma americanum (lone star tick)^ ii

Time point at which active achieved consistent superior efficacy vs. untreated control group¥ 

Day of Study

Credelio

(lotilaner)

Sarolaner

(sarolaner, moxidectin and pyrantel)

NexGard

(afoxolaner)

0

12 hrs

24 hrs

24 hrs

21

12 hrs

48 hrs

48 hrs

28

8 hrs

48 hrs

72 hrs

^Tick counts were evaluated at all 4-, 8-, 12-, 24-, 48-, and 72-hour time points as part of the study design 

¥P<0.05. 

"With a heavier tick season and emergency room visits from tick bites on the riseiv, pet owners should remain vigilant and keep their pets on year-round parasite coverage," Dr. Locklear notes. "We continue to look for opportunities to make parasite protection stronger and evolve research around best-in-class medicines."

Frequently Asked Questions About Ticks and Credelio Quattro:

How fast does Credelio Quattro kill ticks? 

Studies show that lotilaner, the active ingredient in Credelio Quattro kills ticks5  faster6 than the competition.i,ii A 2026 study published in Parasites & Vectors shows that Credelio Quattro achieved significant reduction2 of black-legged ticks within 8 hours of infestation.i A 2024 study shows that lotilaner, the active ingredient in Credelio and Credelio Quattro also has the fastest3 initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ii

Why is it important to kill ticks quickly?

The risk of disease transmission increases the longer a tick remains attached, making rapid speed of kill a critical factor in preventing the transmission of disease. A 2026 study shows that Credelio Quattro was the only product tested that significantly reduced2 black-legged ticks within 8 hours.i

Does Credelio Quattro lose effectiveness to kill ticks1 quickly at the end of the month? 

No. The data shows that Credelio Quattro maintains its 8-hour speed of kill2 on Day 28, whereas competitors showed a decline in performance.i

Are black-legged ticks linked to the red meat allergy in humans?

In the United States, alpha-gal syndrome, or red meat allergy, is usually associated with bites from the lone star tick (Amblyomma americanum); however, two Emerging Infectious Diseases studies link bites from black-legged ticks (deer ticks) and western black-legged ticks to potentially life-threatening alpha-gal syndrome.v Additional work will be needed to determine a possible link, according to the researchers, but this continues to put emphasis on the need for tick bite protection for humans.

To learn more about Credelio Quattro visit CredelioQuattroVet.com.

PM-US-26-1188

Ixodes scapularis (black-legged tick) Based on the time to statistical significance vs. control in a head-to-head study on Day 0 post-treatment and Day 28 for reinfestations comparing Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against Ixodes scapularis. Based on the time to statistical significance vs. control in a head-to-head study comparing Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner).  Based on the time to statistical significance vs control in two separate head-to-head studies. The first study compared Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner) against Amblyomma americanum. The second study compared Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against I. scapularis. Ixodes scapularis (black-legged tick) and Amblyomma americanum (lone star tick) NexGard and NexGard Plus are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. Simparica Trio is a registered trademark of Zoetis Services LLC.

Credelio Quattro, Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2026 Elanco or its affiliates

ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Indications for Credelio Quattro/Credelio Quattro-CA1

Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

Important Safety Information for Credelio Quattro/Credelio Quattro-CA1

Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

Indications for Credelio
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Important Safety Information for Credelio
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

i Reif, K.E., Kollasch, T.M., Locklear, C.L. et al. Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGard® PLUS), or lotilaner (Credelio Quattro™). Parasites Vectors (2026). https://doi.org/10.1186/s13071-026-07559-y
ii  Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313.
iii Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from https://www.cdc.gov/ticks/about/where-ticks-live.html
iv CDC Data Show Weekly ER Visits for Tick Bites Higher Than Usual." Centers for Disease Control and Prevention, 23 Apr. 2026,
v Van Beusekom, Mary. "Research Ties Bites from 2 More Types of Ticks to Red Meat Allergy." CIDRAP (Center for Infectious Disease Research and Policy), 4 Apr. 2025

Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
Media Contact: Season Solorio (765) 316-0233 [email protected]

SOURCE Elanco Animal Health